Age in years (range) | 60.5 | (30 - 81) |
Gender | ||
Male | 56 | (64%) |
Female | 31 | (36%) |
Baseline serum creatinine concentration in mg/dl (± SEM) | 0.81 | (± 0.28) |
Arterial hypertension | 21 | (24%) |
Concomitant nephrotoxic/volume depleting or blood pressure lowering medication | ||
- NSAIDs | 18 (21%) | |
- Loop diuretics | 14 (16%) | |
- Thiazides | 8 (9%) | |
- ACE inhibitor | 6 (7%) | |
- AT2 blocker | 4 (5%) | |
- Aldosterone antagonists | 2 (2%) | |
Preceding chemotherapy | 45 (52%) | |
Liver metastasis | 45 (52%) | |
Group A (treated with capezitabine, rofecoxib and pioglitazone) | Group B (treated with trofosfamid, rofecoxib and pioglitazone) | |
Melanoma | 16 | |
Gastric carcinoma | 13 | |
Colorectal carcinoma | 12 | |
Renal cell carcinoma | 9 | |
Hepatic carcinoma/Klatskin | 7 | |
Sarcoma | 5 | |
Pulmonary adenocarcinoma/SCLC | 3 | |
Pancreatic cancer | 3 | |
Urothelium carcinoma | 3 | |
Gall bladder carcinoma | 3 | |
Breast cancer | 2 | |
Histiozytosis X | 2 | |
Hodgkin/Non-Hodgkin-Lymphoma | 2 | |
Ovarial carcinoma | 2 | |
TNE | 2 | |
Chronic lymphatic leukemia | 1 | |
Cervix carcinoma | 1 |